• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Magle Chemoswed

1.01 SEK10.7, 17.25
Less than 1K followers

MAGLE

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
-70.12 %
-75.00 %
-94.16 %
-94.26 %
-96.37 %
-96.93 %
-97.39 %
-94.97 %

Magle Chemoswed is founded on strategic acquisitions aimed at driving growth and diversifying risk. The Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.

Read more
Market cap
30.57M SEK
Turnover
-
Revenue
282.92M
EBIT %
-44.88 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.8
2026

Interim report Q2'26

2.11
2026

Interim report Q3'26

24.2
2027

Annual report '26

Regulatory press release10.07.2026, 19.04

MAGLE GROUP HAS RESOLVED ON A RESTRUCTURING OF ITS OUTSTANDING DEBT AND CAPITAL STRUCTURE, INCLUDING DEBT-FOR-EQUITY SWAP, ISSUANCE OF SUPER SENIOR BONDS AND DIRECTED SHARE ISSUES

Magle Chemoswed
Regulatory press release30.06.2026, 21.53

Magle Group enters into agreement with Danske Bank regarding repayment schedule and agreement with the bondholders committee regarding the requirement for additional capital

Magle Chemoswed
Regulatory press release30.06.2026, 17.24

Bulletin from the Annual General Meeting in Magle Chemoswed Holding AB (publ)

Magle Chemoswed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release30.06.2026, 13.40

Magle Chemoswed Holding AB (publ) releases Annual Report for 2025

Magle Chemoswed
Regulatory press release26.06.2026, 18.00

Magle Group Announces Change in Publication Date for Annual Report 2025

Magle Chemoswed
Regulatory press release25.06.2026, 21.41

Magle Group announces deferral of interest payment in respect of its bonds, and update to timing of intended financial restructuring

Magle Chemoswed
Regulatory press release23.06.2026, 21.00

Magle Group Announces Change in Publication Date for Annual Report 2025

Magle Chemoswed
Regulatory press release22.06.2026, 16.24

Magle Chemoswed Holding AB (publ) announces successful completion of the written procedure in relation to its senior secured bonds 2025/2028

Magle Chemoswed
Regulatory press release11.06.2026, 22.00

MAGLE GROUP ANNOUNCES AN UPDATE REGARDING THE KEY PRINCIPLES FROM NEGOTIATIONS WITH BONDHOLDERS

Magle Chemoswed
Regulatory press release07.06.2026, 19.08

Magle Chemoswed Holding AB – Update on Financing Arrangements and Ongoing Stakeholder Discussions

Magle Chemoswed
Regulatory press release07.06.2026, 15.25

Magle Group Announces Change in Publication Date for Annual Report 2025

Magle Chemoswed
Press release03.06.2026, 15.13

Redeye: Magle Group (Q1 Review): Restructured operations, focus on turnaround

Magle Chemoswed
Regulatory press release02.06.2026, 14.28

Magle Chemoswed Holding AB (publ) initiates a written procedure to amend the terms and conditions of its senior secured bonds 2025/2028

Magle Chemoswed
Regulatory press release31.05.2026, 12.00

Magle Chemoswed Holding Reports Financial Results For First Quarter 2026

Magle Chemoswed
Regulatory press release28.05.2026, 08.32

Notice to the Annual General Meeting in Magle Chemoswed Holding AB (publ)

Magle Chemoswed
Regulatory press release27.05.2026, 19.26

Magle Group enters into a loan facility agreement of up to SEK 60 million

Magle Chemoswed
Regulatory press release26.05.2026, 16.28

Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ)

Magle Chemoswed
Regulatory press release25.05.2026, 15.00

Calendar Update of the Annual General Meeting 2026

Magle Chemoswed
Regulatory press release11.05.2026, 22.01

MAGLE GROUP HAS RESOLVED ON A SET-OFF ISSUE TO BONDHOLDERS

Magle Chemoswed
Regulatory press release08.05.2026, 09.30

Notice to extraordinary general meeting in Magle Chemoswed Holding AB (publ)

Magle Chemoswed